News Can Pear bud again? Ex-CEO McCann bids for assets Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.